In Brief
Reya and colleagues identify Tetraspanin 3 as a key signal required for AML. Tspan3 deletion leads to improved survival in mouse models of AML and reduced cancer growth in xenografts. Tspan3 loss impairs migration of leukemic cells to SDF suggesting that it may influence oncogenesis by controlling a normal chemokine response.
INTRODUCTION
Acute myelogenous leukemia (AML) is a cancer marked by the rapid and uncontrolled growth of immature cells of the myeloid lineage (Shipley and Butera, 2009 ). Because it is a heterogeneous disease involving a wide array of chromosomal translocations and/or mutations, response to therapy differs widely between subclasses of AML. For example, while leukemias with Flt3 mutations or MLL translocations are generally associated with poor prognosis in both adults and children, those driven by PML/RARa translocations respond well to therapy (Chen et al., 2011; Fernandez et al., 2009; Krivtsov and Armstrong, 2007; Roboz, 2012; Zeisig et al., 2012) . However, despite improvements in outcomes for some subtypes of AML, current treatments that include chemotherapy and bone marrow transplantation remain ineffective for a vast majority of AML patients. Thus, identifying new approaches to more effectively target common regulators of therapy resistant AML remains critically important.
In an effort to identify pathways that mediate the aggressive growth of AML and other hematologic malignancies, we have focused on stem cell programs that are subverted to drive the oncogenic state. One important regulator of such programs is the RNA binding protein Musashi. Musashi 2 (Msi2) has been shown to predict poor prognosis in patients with chronic myelogenous leukemia (CML) and is critical for progression to the blast crisis phase of the disease (Ito et al., 2010) . Msi2 is also highly expressed in several AML lines and can serve as an indicator of poor outcome (Byers et al., 2011; Kharas et al., 2010) . The fact that multiple hematologic malignancies require Msi2 suggested that identifying stem cell programs triggered by Msi2 could lead to the discovery of pathways important for establishing and sustaining disease. Genome-wide expression analysis of Msi-deficient cancer stem cells from blast crisis CML and de novo AML identified genes commonly regulated in both leukemias. This strategy identified Tetraspanin 3 (Tspan3), a recently identified member of the tetraspanin family, as a key downstream target of Msi2 and a potential functional element in myeloid leukemia.
The tetraspanin (tetraspan or TM4SF) family forms a large group of integral membrane proteins possessing four membrane-spanning domains separated by short intracellular and extracellular domains, as well as one long extracellular domain (Hemler, 2005) . Tetraspanins interact with each other and with a variety of different receptors and signaling molecules to organize supramolecular complexes in membranes. Although tetraspanins are expressed across a wide variety of cells and tissue types and are involved in diverse cellular processes such as cell adhesion, proliferation, and immune responses (Wright et al., 2004) , many tetraspanins remain understudied, and the roles they play in normal stem cell biology and in disease remain unknown. This is particularly true of Tspan3, which has been studied in context of oligodendrocyte migration (Tiwari-Woodruff et al., 2001) , and about which little else is known. The regulation of Tspan3 by Msi2 in AML led us to test its role in leukemia development and propagation.
Expression analysis showed that Tspan3 is expressed in the hematopoietic stem/progenitor cells as well as in leukemia, and its pattern of expression closely mirrors that of Msi2. To test the requirement for Tspan3 in cancer, we generated Tspan3 knockout mice. These mice were born healthy and showed no overt defects in development or homeostasis. While the loss of Tspan3 did not affect normal hematopoiesis, it blocked AML self-renewal and propagation in vitro and in vivo. Further, the inhibition of Tspan3 in patient samples led to decreased colony formation in vitro, and leukemic growth in primary patientderived xenografts. Finally, Tspan3 deletion triggered defects in chemokine responsiveness and AML cell migration, which may contribute mechanistically to the defects observed. Collectively, our data identify a critical role for Tspan3 in de novo AML and suggest that Tspan3 may be valuable as a therapeutic target.
RESULTS

Identification of Genomic Programs Important for Myeloid Leukemia
Our previous studies demonstrated that Msi2 is critical for the development of blast crisis CML (Ito et al., 2010) . In addition, consistent with published work with AML cell lines (Kharas et al., 2010) , we found that loss of Msi2 impaired primary AML growth as well. Small hairpin RNA (shRNA)-mediated knockdown of Msi2 led to suppression of colony formation induced by MLL-AF9, MLL-AF9/NRAS, MLL-ENL, MLL-ENL/NRAS, and MLL-AF10 (Figures 1A-1C ; Figures S1A-S1D ). Loss of Msi2 also blocked the in vivo propagation of MLL-AF9 and MLL-AF9/NRAS-driven AML (Figures 1D-1G ; Figures S1E-S1H), as well as primary patient-derived AML cells (Figures 1H and 1I) . Given this shared genetic dependence of two aggressive hematologic malignancies on Msi2, we postulated that analysis of the common molecular programs downstream of Msi2 could identify programs generally important for the propagation of myeloid leukemia.
Genome-wide expression analysis was performed on wildtype and Msi2-null leukemic stem cells from BCR-ABL/NUP98-HOXA9-driven blast crisis CML (bcCML), and from MLL-AF9-driven de novo AML (Figure 2A ). Subsequently, genes that were significantly changed (false discovery rate [FDR] <0.05) following loss of Msi2 in bcCML and in de novo AML were compared and categorized into four groups: concordant (blue), bcCML specific (magenta), AML specific (red), and discordant (i.e., opposing directions, green) ( Figure 2B ). Of these, 319 probes formed a set of concordantly regulated core genes in both malignancies ( Figure 2C) . A gene ontology (GO) analysis on this core gene set regulated in both bcCML and MLL-AF9 leukemia revealed changes in many pathways, the most significant of which were regulation of cell differentiation, cell-surfacereceptor-linked signaling pathways and immune system processes ( Figures S2A-S2C ). The modulation of signals such as Flt3, Sox4, and Pdgfrb, as well as genes regulating apoptosis such as Bid and Bcl2a1, indicated that Msi2 controls, either directly or indirectly, expression of large groups of genes integrally linked to oncogenesis ( Figures 2D and 2E ).
Generation of Tspan3 Knockout Mice
The whole-genome expression analysis not only identified Msi2 as a key upstream regulator of genes implicated in cancer but was of particular value as a database that could be mined to identify additional regulatory signals in this disease. One differentially expressed gene that had not previously been implicated in hematologic malignancies or in any other primary cancer was Tetraspanin 3 (Tspan3), a member of the tetraspanin family of four pass transmembrane proteins. We focused specifically on this because as a cell-surface protein it would be more amenable to targeting via biologics in the long term.
In the normal hematopoietic system, Tspan3 was most highly expressed in stem and progenitor cells ( Figure 2F ) and was critically dependent on the presence of Msi2. Inhibition of Msi2 led to a 5-to 6-fold reduction in Tspan3 levels (Figures 2G and 2H ; Figure S2D ), and ectopic overexpression of Msi2 in stem/ progenitors triggered a rise in Tspan3 ( Figure 2I ). Importantly, TSPAN3 RNA could be specifically immunoprecipitated with MSI2 in a RIP-PCR analysis of human AML cells ( Figure 2J ), suggesting that Msi2 may be a direct regulator of Tspan3; transcripts encoded by the IGF2 and ACTIN genes were not immunoprecipitated by MSI2 and served as negative controls ( Figure 2J ). This together with an earlier report showing that the Msi1 can bind Tspan3 RNA in HEK293T cells (de Sousa Abreu et al., 2009) suggests that Tspan3 is a direct target of both Msi1 and Msi2. Finally, ectopic overexpression of Tspan3 resulted in partial but significant rescue of the colony forming ability of Msi2-null cells ( Figure 2K ), indicating that Tspan3 can act functionally downstream of Msi2 to regulate AML growth. The partial rescue may be because the impact of Msi2 on leukemogenesis is likely to be mediated collectively by programs triggered by multiple genes ( Figure 2C ), with Tspan3 contributing to specific aspects of disease propagation.
To functionally define the role of Tspan3 in AML, we generated knockout mice from Tspan3 genetrap embryonic stem cells (Figure 3A) . Tspan3 mRNA expression in these mutants (denoted as Gt/Gt) was nearly undetectable ( Figure 3B ). Tspan3-null mice were viable and did not display any overt developmental defects; moreover, they had comparable numbers of total bone marrow cells in adult life (6 weeks, Figures 3C-3F ). Importantly, Tspan3-null hematopoietic stem cells (HSCs) showed no functional defects in long-term bone marrow reconstitution following transplantation or in homing ( Figures 3G and S3A) . However, Tspan3-null mice displayed defects in hematopoiesis as they aged. Specifically, older mice exhibited a 40%-60% reduction (except Ter119 + cells, which were reduced by 27%) in the numbers of progenitors and differentiated cells (Figures S3B and S3C) , suggesting that Tspan3 plays a role in protecting hematopoietic cell function during aging.
Tspan3 Is Required for AML Development and Propagation in Mouse Models
To define the role of Tspan3 in leukemia, hematopoietic stem/ progenitor cells (KLS) from wild-type or Tspan3-null mice were infected with MLL-AF9/NRAS and transplanted ( Figure 4A ). Whereas 90% of recipients transplanted with wild-type cells died of leukemia and only 10% survived, 53% of those transplanted with Tspan3-null cells survived, indicating a 5-fold increase in survival ( Figure 4B ). The cKit + Gr1 -leukemia stem cell population expressed Tspan3 at higher levels relative to bulk leukemia, suggesting Tspan3 may be specifically important for these cells ( Figure 4C ). To directly test whether loss of Tspan3 impaired self-renewal of leukemic stem cells, we serially transplanted cKit + cells from wild-type or Tspan3-null tumors. As shown in Figure 4D , 100% of the mice transplanted with wild-type leukemia cells developed leukemia within 69 days, whereas only 31% of mice transplanted with Tspan3-null cKit + cells developed leukemia. Tspan3 loss not only significantly reduced the incidence of leukemia, but also markedly increased the latency of disease ( Figure 4D ). These data indicate that Tspan3 is required for maintaining the selfrenewal of leukemic stem cells and tumor-propagating ability of de novo AML.
To determine whether Tspan3 is also required in established AML, and to rule out the possibility that impaired AML propagation in Tspan3 knockouts could be due to developmental defects, we used shRNA to knock down Tspan3 in established leukemia ( Figure S4A ). AML cells were transduced with control or Tspan3 shRNA and transplanted (Figures 4E and 4F) . Whereas almost all mice transplanted with control leukemia succumbed to disease, leukemia formation was significantly impaired with Tspan3 inhibition ( Figure 4E ), with only 50%-68% of mice transplanted with Tspan3 knockdown MLL-AF9 or MLL-AF9/NRAS AML succumbing to disease. Consistent with this, Tspan3 deficient leukemia cells were less able to form colonies in vitro ( Figure 4G ). These data indicate that Tspan3 is critical for MLLdriven leukemia, and that its inhibition can impair propagation of established AML in vitro and in vivo. Interestingly, not only was the impact of Tspan3 deletion on AML growth strikingly similar to that seen with Msi2 inhibition (Figure 1 ), but Tspan3 loss also phenocopied Msi2 loss at a molecular level. Thus, genes selected from the expression analysis of Msi2 À/À AML cells were retested on Tspan3 À/À AML cells. These genes, which included Flt3, Sox4I, and Pecam1, reflected the same pattern of dysregulation seen with Msi2 deletion ( Figure 4H ). Collectively, these data, together with complementation analysis presented earlier ( Figure 2K ), support the possibility that Tspan3 is a functional downstream mediator of Msi2 in AML.
To define whether Tspan3 may be a more general regulator of AML driven by distinct alleles, we tested the role of Tspan3 in a non-MLL-driven model of AML. To this end, we infected control or Tspan3-null HSCs with a virally delivered AML-ETO9a allele together with mutant NRAS and tested leukemic growth in vitro and in vivo. Tspan3 deletion showed a strong trend toward improved survival (p = 0.06) and led to an increase in median survival in vivo: specifically, while the median survival of control mice was 24 days, the deletion of Tspan3 in AML cells extended latency to 43 days, thus almost doubling the survival time ( Figures S4B and S4C) . Moreover, to determine the repopulating ability of leukemic cells, colony forming ability of AML-ETO9a/NRAS-driven leukemic cells obtained from control or Tspan3-null leukemia was determined. Leukemic cells from Tspan3-null leukemia formed 5-fold fewer colonies as compared to controls, suggesting that Tspan3 is needed for self-renewal in vitro ( Figure S4D ). These data collectively indicate that the influence of Tspan3 is not limited to MLL-AF9-driven de novo AML but may be broader across other classes of the disease.
Tspan3 Is Required for a Normal Response to the Chemokine CXCL12/SDF-1 To gain insight into the mechanisms by which Tspan3 controls AML propagation, we first examined cell proliferation and apoptosis. In vivo BrdU delivery indicated that Tspan3-deficient leukemic cells proliferate less ( Figures S4E and S4F) . Further, no difference in apoptosis was seen using annexin V binding, although a mild increase in the frequency of cells undergoing necrosis was noted ( Figures S4G and S4H) .
The fact that neither the defects in proliferation or cell survival in Tspan3-deficient cells were as severe as defects observed in AML propagation ( Figures 4A-4G ) suggested that Tspan3 may operate through additional mechanisms in context of the microenvironment in vivo. We thus tracked the spatial distribution of wild-type and Tspan3-null leukemic cells within the bone marrow through in vivo imaging in real time. While control AML cells localized to an area with vascular beds known to be rich in SDF-1 on both sides of the central sinus within the calvarium (Colmone et al., 2008; Paxinos and Franklin, 2012; Sipkins et al., 2005) , Tspan3-null AML cells were located predominantly in the central sinus distant from SDF-1-enriched areas (Figure 5A) . Consistent with these defects in vivo, Tspan3 deletion impaired the capacity of leukemic cells to migrate toward SDF in vitro. While 28% of the wild-type leukemia cells migrated toward SDF-1 within 4 hr in a Boyden chamber assay, 2.5-fold fewer Tspan3-null cells (11%) migrated within the same period of time ( Figure 5B ). Defects in chemokine responsiveness were coupled with defects in receptor activation, as loss of Tspan3 led to significantly reduced levels of activated (Ser339 phosphorylated) CXCR4 (Figures 5C and 5D ; Figure S5A ). To test whether CXCR4 acts functionally downstream of Tspan3, we inhibited CXCR4 using shRNAs and AMD3100, a small-molecule inhibitor of CXCR4 signaling. Inhibition of CXCR4 through either strategy resulted in a marked loss of colony forming ability of cKit + AML cells ( Figures 5E and S5B ). Further, in vivo delivery of AMD3100 showed significantly prolonged survival (Figure 5F ), and profoundly altered the in vivo localization of AML cells ( Figures 5G and 5H ), phenocopying the effects of Tspan3 deletion. CXCR4 expression could also rescue the defects triggered by Tspan3 or Msi2 deletion. Thus, overexpression of active CXCR4 Representative data from two independent experiments are shown. Error bars, SEM. *p < 0.05. See also Figure S2 .
partially rescued in vitro colony formation and in vivo chimerism of Tspan3 À/À cells ( Figures S5C and S5D) , as well as the colony forming defects caused by the loss of Msi2 ( Figure S5E ). Since CXCR4 rescued Tspan3-null colony forming defects in the absence of stromal cells in vitro, we tested whether AML cells themselves were a source of SDF. Immunofluorescence analysis indicated that 14% of primary MLL-leukemia cells expressed SDF-1 protein ( Figure S5F ), suggesting that CXCR4-mediated signaling may be sustained in these cells through an autocrine loop. Collectively, these data suggest that Tspan3 may influence AML growth, at least in part, by controlling CXCR4-mediated chemokine responsiveness.
TSPAN3 Is Required for Growth of Human Myeloid Leukemia
To define whether Tspan3 is relevant for human disease, we analyzed its expression in patient samples of both bcCML and de novo AML. TSPAN3 expression increased with CML progression ( Figure 6A ), displaying a remarkable parallel with the rise in MSI2 expression (Ito et al., 2010) . Further, TSPAN3 expression was significantly higher in samples from pediatric patients with relapsed AML ( Figure 6B ) compared to AML in remission or healthy samples (Yagi et al., 2003) . Blocking Tspan3 through shRNA delivery ( Figure S6 ) significantly impaired colony wild-type controls. Genes were selected from the genomic analysis of Msi2-null leukemic cells shown in Figure 2 ; n = 3. Error bars, SEM. *p < 0.05. See also Figure S4 .
formation of both bcCML patient samples in vitro as well as de novo AML patient samples with MLL rearrangements ( Figures  6C-6E ). In addition, consistent with data from mouse models of non-MLL-driven AML, TSPAN3 inhibition blocked growth of patient samples with non-MLL rearrangements both in vitro ( Figures 6F and 6G ) as well as in xenografts ( Figures 6H  and 6I ). These results strongly suggest that Tspan3 is important for the propagation of a broad range of human myeloid leukemias.
DISCUSSION
To identify the mechanisms that drive aggressive leukemias, we have focused on stem cell pathways that become reactivated in cancer. In particular, to define pathways important in this malignancy we have mapped signals activated by Msi2, a key regulator of leukemic growth. This led to identification of the tetraspanin superfamily member Tspan3 as a critical regulator of de novo AML. We found that loss of Tspan3 significantly impairs AML propagation in mouse models both in vitro and in vivo.
Further, inhibition of Tspan3 in patient-derived AML samples inhibits their growth in vitro and in xenografts, indicating that Tspan3 is functionally important for human disease as well. As a possible mechanism, we found that Tspan3-null AML cells exhibit a marked inability to respond to the chemokine SDF-1 and subsequently mislocalize within the niche. Msi2's role in primary AML, coupled with its role in bcCML, indicates that Msi2 is a broadly important regulator of aggressive hematologic malignancies. Genome-wide analysis to compare gene expression patterns in leukemic stem cells between Msi2-deficient bcCML and AML revealed genes that were altered by loss of Msi2 specifically in either bcCML or AML, but also identified a cluster of core genes regulated concordantly in both cancers. This core set includes key factors and signaling pathways through which Msi2 could impact cell fate and represents a valuable resource for continued mining of pathways that are critical for leukemia stem cell maintenance and that could be targeted in the long term. Importantly, these data show that several genes critical in solid cancers, such as Flt3, Pdgfrb, and ErbB3, are extinguished upon Msi2 loss, raising the intriguing possibility that activation of these signals may depend on Msi2 expression in solid cancers as well.
A key finding reported here is that Tspan3 is critically required for de novo AML propagation. Tspan3 belongs to the Tetraspanin superfamily, an understudied family of proteins that includes 34 members in the mouse and 33 members in humans (GarciaEspañ a et al., 2008) . These cell-surface molecules play a wide variety of roles in distinct cells and tissues. Some Tetraspanin family members have been associated with tumor development (Boucheix et al., 2001; Hemler et al., 1996) ; for example, CD9 and CD231 (TALLA1) have been identified as biomarkers in leukemias, and CO-029 and SAS have been implicated in carcinomas and sarcomas (Jankowski et al., 1994; Szala et al., 1990) . Tspan3 itself may play a role in other cancers: for example, its inhibition blocks the growth of a colon cancer cell line in vitro (Moss et al., 2007) . Our work showing that Tspan3 plays a critical role in leukemia suggests that it will be important to investigate whether Tspan3 is important for the growth of primary solid cancers in vivo as well.
Our work also establishes a connection between Tspan3 and SDF-CXCR4 chemokine signaling. Consistent with this, Tspan3 loss led to remarkable defects in SDF-1 responsiveness and CXCR4 activation, and CXCR4 activation complemented defects triggered by loss of Msi2 or Tspan3. Our own data as well as significant prior work suggest that CXCR4 can have a powerful influence on AML. Our findings that CXCR4 inhibition profoundly impairs MLL-driven AML complements previous work showing that blocking CXCR4 reduces AML burden driven by other alleles (Uy et al., 2012; Zeng et al., 2009 ). Further, SDF-1/ CXCR4 signaling has been shown to influence not only the proliferation, survival, and differentiation of AML (Tavor et al., 2004 (Tavor et al., , 2008 Zeng et al., 2009 ) but also the interaction between AML and the microenvironment (Tavor et al., 2004) . Finally, CXCR4 has been previously shown to be associated with chemoresistance and poor prognosis Nervi et al., 2009; Rombouts et al., 2004; Sison et al., 2013; Spoo et al., 2007) . By collectively identifying CXCR4 as an important element in controlling leukemia propagation, these data underscore the importance of CXCR4's link with Tspan3 in multiple contexts. How Tspan3 influences SDF/CXCR4 signaling is not yet clear; however, the fact that tetraspanin-enriched microdomains (TEMs) facilitate membrane fusion and signal transduction suggests that Tspan3 could modulate the activity of CXCR4 in spatially defined TEMs as well. Thus, enabling chemokine (shTSPAN3) and transplanted into sublethally irradiated NSG recipients, and chimerism was determined after 2 months. Data from two independent experiments are displayed relative to control set at 1. Error bars, SEM. n = 4, *p < 0.05. See also Figure S6 .
responsiveness may be a significant part of the mechanism by which Tspan3 controls myeloid leukemia, and elucidating these links will be an important area for further work. Previously, several other signaling molecules have been shown to be important in de novo AML propagation. Loss of the FOXO and HOX transcription factors or the transcriptional co-activator beta-catenin impairs AML growth in vivo (Faber et al., 2009; Sykes et al., 2011; Wang et al., 2010) , and deletion of PBX-3, which increases the DNA binding activity of HOX proteins, leads to similar results (Li et al., 2013) . A role for the Polycomb group member Bmi-1 in the proliferation of AML stem/progenitor cells has also been demonstrated (Lessard and Sauvageau, 2003) . How these and other pathways are integrated with each other and with Tspan3 and whether they act in a hierarchy will be important to define in order to fully map the molecular networks that regulate myeloid leukemia.
The development of the Tspan3 knockout mouse reported here has significance beyond the findings in this work. Because so little is known about Tspan3 function in vivo, these mice represent a valuable resource for defining the genetic role of Tspan3 in other systems. Although our data did not reveal any overt defects, detailed analyses of specific tissues are needed to assess any impact on normal function. For example, Tspan3 has been implicated in migration of oligodendrocytes, the myelin-producing cells of the CNS (Tiwari-Woodruff et al., 2001) . Thus, analysis of brain and spinal cord function will be essential to determine whether any defects in myelination or neurotransmission occur in Tspan3-null mice. In addition to their use in understanding the role of Tspan3 in normal cellular function, Tspan3-null mice have the potential to be invaluable in identifying the role of Tspan3 in other hematologic malignancies and solid cancers.
Our finding that Tspan3 is necessary for the growth and progression of AML in distinct mouse models as well as in diverse patient-derived AML samples suggests that inhibition of Tspan3 signaling may be an effective strategy for blocking leukemia growth. This is a particularly attractive possibility because the cell-surface expression of Tspan3 makes it well suited for antibody-mediated therapy. Rituximab and TRU-016, which target the Tspan-like molecule CD20 and the Tspan family member CD37 respectively, represent precedents for Tspan targeting by monoclonal antibodies (Robak et al., 2009; Robak, 2010) . Rituximab is in use clinically for the treatment of chronic lymphocytic leukemia, follicular lymphoma, and diffuse large B cell lymphoma, and TRU-016 is being tested in trials against chronic lymphocytic leukemia. The fact that Tspan3 knockout mice are viable, and do not display overt developmental defects, provides a potential therapeutic window for anti-Tspan3 immunotherapy. Collectively, our findings raise the possibility that targeting Tspan3 could provide a new approach for therapy of aggressive adult and pediatric leukemias. /SzJ). All mice were 1-5 months of age unless otherwise specified. Msi2 mutant mice B6;CB-Msi2
Gt(pU-21T)2Imeg have been described previously (Ito et al., 2010) . Mice were bred and maintained in the animal care facility at University of California San Diego. All animal experiments were performed according to protocols approved by Duke University and University of California San Diego Institutional Animal Care and Use Committees.
Generation of Tspan3 Knockout Mice
Tspan3 knockout mice were generated from mouse embryonic stem cell line NPX312 (strain 129/Ola; Baygenomics, https://www.mmrrc.org/). The gene trap vector (pGT1 TMpfs) was inserted between exons 3 and 4. These cells were injected into C57BL/6 blastocysts, which were then implanted into pseudo pregnant females. High-contribution chimeras were obtained. Chimeric mice were backcrossed to C57BL/6 mice and knockout mice were generated by breeding offspring of heterozygous mice. Experiments were performed with mice of mixed genetic background.
Generation and Analysis of Leukemic Mice
Bone marrow KLS cells were sorted and cultured overnight in RPMI media (Invitrogen) supplemented with 20% fetal bovine serum, stem cell factor (SCF, 100 ng/ml, R&D Systems), and interleukin-3 (IL-3) and IL-6 (10 ng/ml, R&D Systems). Subsequently, cells were retrovirally infected with MSCV-MLL-AF9-IRES-GFP (or tNFGR) to generate MLL-AF9 leukemia, MSCV-MLL-AF9-IRES-GFP (or tNFGR) and MSCV-NRAS-IRES-YFP to generate MLL-AF9/NRAS leukemia, or MSCV-AML-ETO9a-IRES-huCD2 and MSCV-NRAS-IRES-YFP to generate AML-ETO9a/NRAS leukemia. Doubly infected or unsorted cells collected 48 hr post-infection were transplanted retro-orbitally into B6 recipients. Recipients were sublethally irradiated (4-6 Gy) for MLL-driven leukemia and lethally irradiated for AML-ETO9a-driven leukemia (9.5 Gy). For secondary transplantation, GFP + /YFP + and cKit + cells were sorted from primary transplanted mice, and 1,000-3,000 cells were transplanted per mouse. Diseased mice were analyzed as previously described (Zimdahl et al., 2014) .
In Vivo Imaging of Leukemia Cells MLL-AF9/ NRAS leukemic WT and Tspan3-null cells (50,000-200,000 cells/ mouse) were injected into sublethally irradiated Actin-dsRed or Actin-CFP mice. The calvarial bone marrow was imaged 8-15 days after transplants. Images were acquired by the Leica LAS AF 2.7.3 software with TCS SP5 upright DM600 CFS Leica confocal system using the HCX APO L 20x/ 1.00 W Leica Plan Apochromat objective.
Genome-wide Expression Analysis
Lin -bcCML cells and Lin -Sca1 -cKit + AML cells were fluorescence-activated cell sorted, and total cellular RNA was purified. RNAs were amplified, labeled, and hybridized onto Affymetrix GeneChip Mouse Genome 430 2.0 Arrays, and raw hybridization data were collected (Asuragen). Expression level data were normalized using a multiple-loess algorithm as previously described (Sasik et al., 2004) . Probes whose expression level exceeded a threshold value in at least one sample were considered detected. The threshold value was found by inspection from the distribution plots of log 2 expression levels. Detected probes were sorted according to their q-value, which is the smallest false discovery rate (FDR) (Klipper-Aurbach et al., 1995) at which the gene is called significant. An FDR value of a is the expected fraction of false positives among all genes with q % a. FDR was evaluated using Significance Analysis of Microarrays and its implementation in the official statistical package samr (Tusher et al., 2001) . To prevent unwarranted variances, the percentile of SD values used for the exchangeability factor s0 in the regularized t-statistic was set to 50. The probe list, sorted by q-value in ascending order, was translated into Entrez gene ID's and parsed so that where several different probes represent the same gene, only the highest-ranking probe was kept for further analysis. The sorted list of genes was subjected to a non-parametric variant of the Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) , in which the p value of a gene set was defined as the minimal rank-order p value of a gene in the gene set rather than the Kolmogorov-Smirnov statistic as in GSEA. Briefly, let r k be the k-th highest rank among a gene set of size N. The rank-order p value p k of this gene is the probability that among N randomly chosen ranks without replacement, the k-th highest rank will be at least r k . The p value of a gene set was defined as the smallest of all p k . Finding the p value of a gene set of size N requires calculation of N rank-order p values; however, there is no need to adjust the p values for the number of genes tested as the tests are highly statistically dependent. A Bonferroni adjustment of gene set p values for the number of gene sets tested was performed. Gene sets with adjusted p values % 0.05 were reported. Heatmaps were created using inhouse hierarchical clustering software and the colors qualitatively correspond to fold changes.
Statistical Analysis
The statistical analysis was carried out using the t test, Mann Whitney test, and log-rank test.
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